|Titre :||New synthetic opioids: Part of a new addiction landscape (2019)|
|Auteurs :||L. KARILA ; M. MARILLIER ; B. CHAUMETTE ; J. BILLIEUX ; N. FRANCHITTO ; A. BENYAMINA|
|Type de document :||Article : Périodique|
|Dans :||Neuroscience and Biobehavioral Reviews (Vol.106, November 2019)|
|Article en page(s) :||133-140|
|Discipline :||PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)|
Thésaurus mots-clésDROGUES DE SYNTHESE ; FENTANYL ; OPIOIDES ; FACTEUR DE RISQUE ; MORBIDITE ; EFFET SECONDAIRE ; PHARMACOLOGIE ; MORTALITE ; SURDOSE ; TOXICITE
Synthetic opioids (SO) are a major risk for public health across the world. These drugs can be divided into 2 categories, pharmaceutical and non-pharmaceutical fentanyls. A new generation of SO has emerged on the drug market since 2010. North America is currently facing an opioid epidemic of morbi-mortality, caused by over-prescription of opioids, illegally diverted prescribed medicines, the increasing use of heroin and the emergence of SO. Furthermore, this opioid crisis is also seen in Europe. SO are new psychoactive substances characterized by different feature such as easy availability on the Internet, low price, purity, legality, and lack of detection in laboratory tests. They have not been approved or are not recommended for human use. Opioid misuse is associated with somatic and psychiatric complications. For many substances, limited pharmacological information is available, increasing the risk of harmful adverse events. Health actors and the general population need to be clearly informed of the potential risks and consequences of the diffusion and use of SO.
A new generation of synthetic opioids(SOs), structurally different from fentanyl, has emerged on the drug market since 2010.
SOs are found in powder, tablet or liquid forms.
Products are highly concentrated in psychoactive substances and only small quantities are necessary to generate effects.
Acute and delayed toxic effects of these opioids have been reported, depending on the particular nature of the product.
A number of somatic, psychiatric and fatalities has been reported.
|Domaine :||Autres substances / Other substances|
|Sous-type de document :||Revue de la littérature / Literature review|
|Affiliation :||Addiction Research and Treatment Center, Paul Brousse Hospital, Paris-Sud University, INSERM U1000, Villejuif, France|